Page 15 - Confidence Interval News Today

Brendon Neuen, MBBS, PhD, discusses the results of a study he presented at AHA 2023 estimating the lifetime benefit of combination therapy in patients with type 2 diabetes and albuminuria.

ORBITA-2 trial: Percutaneous coronary intervention improved chest pain and quality of life vs. placebo in stable angina patients.

The MINT trial, which included 3504 patients with acute MI and anemia, shows a trend favoring liberal transfusion, indicating a potential for improved outcomes.

Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.

Dealer leads large US banks on curtailing market risk

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) said that primary analysis of phase 3 SIENDO study of selinexor maintenance therapy in advanced or...

Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.

In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.